Connect with us

Hi, what are you looking for?

Thursday, Oct 6, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Poland approves Tilray Medical products for distribution and wholesale

Tilray’s products are now approved by the Polish Ministry of Health

Tilray Medical launches 'CannaPoints" program
Image via Tilray

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) medical division keeps on expanding its presence across Europe and added Poland to its distribution list.

On Wednesday, the cannabis producer with multinational operations announced its products are now approved by the Polish Ministry of Health for pharmaceutical distribution and wholesale.

In Poland, the company has established multiple partnerships with pharmaceutical companies to distribute both Tilray branded and unbranded products. Polish patients are able to access cannabis via medical prescriptions.

Read more: Tilray Medical expands U.K. portfolio

Read more: Luxembourg health authorities visit Tilray Medical facilities in Portugal

“I’m extremely proud of our team in Europe for once again expanding our approved authorization for Tilray Medical products across Europe. Tilray will continue to advocate for reasonable patient access to reliable and high-quality medical cannabis in Europe and countries around the world,” CSO Denise Faltischek said.

Tilray Medical is an international provider of EU GMP-certified medical cannabis products in 21 countries and carries brands including Tilray, Aphria, Broken Coast and Symbios. It is one of the first companies in Canada to build a production facility in Europe and is now one of the largest suppliers of medical pot.

Company stock went down by 2.41 on Wednesday to $5.26 on the Toronto Securities Exchange.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like


The company also released 7 new products under its Tilray and Aphria brands


Flagship product from company's medical cannabis division now set for clinical trial use


The platform has been launched in Germany, France, the United Kingdom and Portugal


The company says its portfolio is now the broadest in cannabis flower in the U.K. market